Intelligence Β· Patent portfolio
United Therapeutics Europe Patents
Full USPTO pharma patent portfolio for United Therapeutics Europe β grant dates, expiration, and drug cross-links.
- Patents
- 3,720
- Expiring β€24m
- 234
Quick answer
United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months β use filters for patent-cliff planning.
-
US 6046200
Compositions having neuroprotective and analgesic activity
expired -
US 6046228
Anti-viral pharmaceutical compositions containing saturated 1,2-dithiaheterocyclic compounds and uses thereof
expired -
US 6045802
Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
expired -
US 6045789
Bystander effect tumoricidal therapy by expressing an HSV-tk gene
expired -
US 6046175
Procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis
expired -
US 6039957
Oligomeric HIV-1 envelope glycoproteins
expired -
US 6040334
Use of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme a reductase as a modality in cancer therapy
expired -
US 6037376
Methods for therapy of cancer
expired -
US 6033708
Method for producing sterile filterable liposome dispersion
expired -
US 6033905
Gibbon ape leukemia virus-based retroviral vectors
expired -
US 6024958
Polypeptide fragments capable of competition with Streptococcus mutans antigen I/II
expired -
US 6025468
Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
expired -
US 6022685
Methods and compositions for detecting anti-hepatitis E virus activity
expired -
US 6019981
Modified live Edwardsiella ictaluri against enteric septicemia in channel catfish
expired -
US 6018102
Ubiquitin-lytic peptide fusion gene constructs, protein products deriving therefrom, and methods of making and using same
expired -
US 6017957
Partial agonists of the strychnine insensitive glycine modulatory site of the N-methyl-D-aspartate receptor complex as neuropsychopharmacological agents
expired -
US 6017880
Inhibition of retrovirus infection
expired -
US 6015876
Method of using cyanovirins
expired -
US 6013206
Process for the formation of high aspect ratio lipid microtubules
expired -
US 6013433
Baculovirus expression vectors and recombinant antigens for detecting type-specific antibodies to herpes simplex virus
expired -
US 6013638
Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
expired -
US 6010695
Saccharomyces boulardii treatment to diminish campylobacter and salmonella in poultry
expired -
US 6010905
Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells
expired -
US 6011002
Circularly permuted ligands and circularly permuted chimeric molecules
expired
Frequently asked questions
How many patents does United Therapeutics Europe have?
3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do United Therapeutics Europe patents expire?
234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory